BRAIN takes majority stake in AnalytiCon Discovery
Will combine the disciplines of biotechnology and natural product chemistry
German biotechnology company BRAIN has bought the majority of shares in natural product specialist AnalytiCon Discovery, forming a partnership in the rapidly growing health and nutrition sector.
Through the purchase BRAIN has gained access to a range of natural products, micro-organisms, plants, gene libraries and the associated technologies required for identification, development and production of products based on natural substances for consumers and business partners.
The alliance combines many years of research and development in the field of natural products and natural extracts with technology for the detection of novel biological activity and subsequent structure-efficacy relationships.
Both companies have more than 20 years of research and development experience in an industrial environment and have already worked together successfully on a variety of industrial projects for about 10 years.
The management and some key personnel of AnalytiCon have joined BRAIN.
Further details of the transaction have not been disclosed.
The alliance combines the disciplines of biology and natural product chemistry. It also enhances access to natural resources as, in addition to a number of diverse micro-organisms, an extensive range of secondary metabolisms of plants that are a source of natural products and innovative production systems are also available.
BRAIN and AnalytiCon aim to work together to find and implement the most economic solutions to emerging technical issues.
'AnalytiCon has been working intensively on its Drug Discovery units within the pharmaceutical industry for several years. This alliance makes it possible to further bridge the gap between the pharmaceutical, food and cosmetics industries,' said Lutz Müller-Kuhrt, CEO of AnalytiCon.
'Through this new alliance with its long-standing partner BRAIN, the company will be strengthened further but will continue to operate independently on the market.'
Holger Zinke, CEO of BRAIN, added: 'The synergy between the disciplines of biotechnology and natural product chemistry established in the alliance brings the two partners to a key position for fully integrated drug development.'
